Intelgenx Technologies Corp (IGXT)
0.167
0.00 (0.00%)
USD |
OTCM |
May 17, 16:00
Intelgenx Technologies Enterprise Value: 41.78M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 41.78M |
| May 16, 2024 | 41.78M |
| May 15, 2024 | 42.92M |
| May 14, 2024 | 41.26M |
| May 13, 2024 | 41.40M |
| May 10, 2024 | 40.38M |
| May 09, 2024 | 42.31M |
| May 08, 2024 | 39.88M |
| May 07, 2024 | 45.80M |
| May 06, 2024 | 45.80M |
| May 03, 2024 | 40.89M |
| May 02, 2024 | 43.79M |
| May 01, 2024 | 44.05M |
| April 30, 2024 | 40.93M |
| April 29, 2024 | 40.56M |
| April 26, 2024 | 41.25M |
| April 25, 2024 | 41.72M |
| April 24, 2024 | 38.81M |
| April 23, 2024 | 41.24M |
| April 22, 2024 | 42.29M |
| April 19, 2024 | 41.43M |
| April 18, 2024 | 42.31M |
| April 17, 2024 | 40.56M |
| April 16, 2024 | 44.05M |
| April 15, 2024 | 42.31M |
| Date | Value |
|---|---|
| April 12, 2024 | 44.94M |
| April 11, 2024 | 44.11M |
| April 10, 2024 | 45.28M |
| April 09, 2024 | 44.10M |
| April 08, 2024 | 43.00M |
| April 05, 2024 | 42.13M |
| April 04, 2024 | 44.93M |
| April 03, 2024 | 43.18M |
| April 02, 2024 | 41.96M |
| April 01, 2024 | 42.74M |
| March 28, 2024 | 43.35M |
| March 27, 2024 | 44.75M |
| March 26, 2024 | 42.66M |
| March 25, 2024 | 42.05M |
| March 22, 2024 | 40.56M |
| March 21, 2024 | 41.03M |
| March 20, 2024 | 39.79M |
| March 19, 2024 | 41.29M |
| March 18, 2024 | 42.31M |
| March 15, 2024 | 41.48M |
| March 14, 2024 | 41.48M |
| March 13, 2024 | 40.83M |
| March 12, 2024 | 41.48M |
| March 11, 2024 | 41.61M |
| March 08, 2024 | 43.53M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
18.57M
Minimum
Apr 06 2020
101.65M
Maximum
Jun 17 2021
44.09M
Average
41.48M
Median
Mar 14 2024
Enterprise Value Benchmarks
| Acasti Pharma Inc | 0.1704M |
| Aurinia Pharmaceuticals Inc | 473.30M |
| Edesa Biotech Inc | 11.83M |
| Lexaria Bioscience Corp | 35.42M |
| Xenon Pharmaceuticals Inc | 2.304B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.38M |
| Revenue (Quarterly) | 0.426M |
| Total Expenses (Quarterly) | 2.397M |
| EPS Diluted (Quarterly) | -0.01 |
| Gross Profit Margin (Quarterly) | -27.00% |
| Profit Margin (Quarterly) | -323.9% |
| Earnings Yield | -35.93% |
| Normalized Earnings Yield | -35.93 |